Sep 12, 2022 / 11:00AM GMT
Thomas Year - H.C. Wainwright & Co.
Hello, everyone. Welcome to the H.C. Wainwright 24th Annual Global Investment Conference. This is Thomas [Year] from H.C. Wainwright.
For our next presentation, we have Hans Schambye. He's the CEO of Galecto, a clinical stage company developing novel treatments for cancer and fibrosis.
Hans, very happy to have you with us. Please go ahead.
Hans Schambye - Galecto, Inc. - CEO
Thanks a lot, Thomas. We're very happy to be here. Hello, everybody. I'm happy to introduce you to Galecto.
So I will be making forward-looking statements, and you can find these on our homepage. Galecto is well capitalized, clinical stage biotech. We have very near-term catalysts. We have announced that we will be reporting data this [quarter].
We have a platform developing [single] molecule-based pharmaceuticals for the treatment of oncological and fibrotic diseases. We're working on two different proteins: galectin-3 and LOXL2, (technical difficulty) both been shown to play critical roles in the overlapping
Galecto Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
